Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Youness Lagoubi, Mohamed Tahar Sfar & Jorge A. Gomez. (2022) A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Bruce Cm Wang, Nathorn Chaiyakunapruk, Shuiqing Zhu, Joseph B. Babigumira, Wesley Furnback, Ramaa Chitale, Amgad Gamil, Kun Zhao & Matt Wasserman. (2022) A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019). Expert Review of Vaccines 21:7, pages 885-898.
Read now
Read now
Hua Zhou, Jinchun He, Bin Wu & Datian Che. (2018) Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Human Vaccines & Immunotherapeutics 14:6, pages 1444-1452.
Read now
Read now
Xu-Hao Zhang, Oscar Leeuwenkamp, Kyu-Bin Oh, Young Eun Lee & Chul-Min Kim. (2018) Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Human Vaccines & Immunotherapeutics 14:1, pages 85-94.
Read now
Read now
Matt Wasserman, Heather L Sings, Dylan Jones, Sarah Pugh, Margaret Moffatt & Raymond Farkouh. (2018) Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines 17:1, pages 71-78.
Read now
Read now
Paolo Castiglia, Lorenzo Pradelli, Stefano Castagna, Veronica Freguglia, Giorgio Palù & Susanna Esposito. (2017) Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Human Vaccines & Immunotherapeutics 13:10, pages 2307-2315.
Read now
Read now
Raymond A Farkouh, Rogier M Klok, Maarten J Postma, Craig S Roberts & David R Strutton. (2012) Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Review of Vaccines 11:10, pages 1235-1247.
Read now
Read now
Articles from other publishers (22)
Peter Murphy, Sebastian Hinde, Helen Fulbright, Louise Padgett & Gerry Richardson. (2023) Methods of assessing value for money of UK-based early childhood public health interventions: a systematic literature review. British Medical Bulletin 145:1, pages 88-109.
Crossref
Crossref
Mariska M. J. Scheffer, Luc E. Coffeng & James F. O’Mahony. (2023) Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: a systematic review. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Crossref
Chun-Yi Lu, Ching-Hu Chung, Li-Min Huang, Eliza Kruger, Seng-Chuen Tan, Xu-Hao Zhang & Nan-Chang Chiu. (2020) Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
A. Løchen & R.M. Anderson. (2020) Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clinical Microbiology and Infection 26:1, pages 60-70.
Crossref
Crossref
Alen Marijam, Jan Olbrecht, Alev Ozakay, Volkan Eken & Kinga Meszaros. (2019) Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value in Health Regional Issues 19, pages 34-44.
Crossref
Crossref
Michele Wilson, Matt Wasserman, Taj Jadavi, Maarten Postma, Marie-Claude Breton, Francois Peloquin, Stephanie Earnshaw, Cheryl McDade, Heather Sings & Raymond Farkouh. (2018) Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infectious Diseases and Therapy 7:3, pages 353-371.
Crossref
Crossref
Lijoy Varghese, Louise Talbot, Andrea Govender, Xu-Hao Zhang & Bruce A. Mungall. (2018) A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Applied Health Economics and Health Policy 16:3, pages 331-345.
Crossref
Crossref
Xiao Jun Wang, Ashwini Saha & Xu-Hao Zhang. (2017) Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
Ellen R. S. Rafferty, Heather L. Gagnon, Marwa Farag & Cheryl L. Waldner. (2017) Economic evaluations of vaccines in Canada: a scoping review. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
Liv S. Nymark, Tarang Sharma, Alexander Miller, Ulrika Enemark & Ulla Kou Griffiths. (2017) Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine 35:49, pages 6828-6841.
Crossref
Crossref
Cristiano Alicino, Chiara Paganino, Andrea Orsi, Matteo Astengo, Cecilia Trucchi, Giancarlo Icardi & Filippo Ansaldi. (2017) The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine 35:43, pages 5776-5785.
Crossref
Crossref
Alexander Kuhlmann & J.-Matthias Graf von der Schulenburg. (2016) Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. The European Journal of Health Economics 18:3, pages 273-292.
Crossref
Crossref
Agustín Ciapponi, Alison Lee, Ariel Bardach, Demián Glujovsky, Lucila Rey-Ares, María Luisa Cafferata, Pilar Valanzasca & Sebastián García Martí. (2016) Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis. Value in Health Regional Issues 11, pages 24-34.
Crossref
Crossref
Jaime E Ordóñez & John Jairo Orozco. (2015) Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Effectiveness and Resource Allocation 13:1.
Crossref
Crossref
David Bin-Chia Wu, Nathorn Chaiyakunapruk, Huey-Yi Chong & Philippe Beutels. (2015) Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014). Vaccine 33:14, pages 1633-1658.
Crossref
Crossref
Makoto Shiragami, Akiko Mizukami, Oscar Leeuwenkamp, Tomas Mrkvan, Emmanuelle Delgleize, Yuichi Kurono & Satoshi Iwata. (2014) Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children. Infectious Diseases and Therapy 4:1, pages 93-112.
Crossref
Crossref
Datian Che, Hua Zhou, Jinchun He & Bin Wu. (2014) Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. BMC Health Services Research 14:1.
Crossref
Crossref
Syed Aljunid, Namaitijiang Maimaiti, Zafar Ahmed, Amrizal Muhammad Nur, Zaleha Md Isa, Soraya Azmi & Saperi Sulong. (2014) Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme. Value in Health Regional Issues 3, pages 146-155.
Crossref
Crossref
Xu-Hao Zhang, Maria Carmen Nievera, Josefina Carlos, Marilla Lucero, Gyneth Bibera, Maria Isabel Atienza, Oleksandr Topachevskyi & Cecilia Gretchen Navarro-Locsin. (2014) Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines. Value in Health Regional Issues 3, pages 156-166.
Crossref
Crossref
Katelijne van de Vooren, Silvy Duranti, Alessandro Curto & Livio Garattini. (2013) Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies. PharmacoEconomics 32:1, pages 29-45.
Crossref
Crossref
Jorge Alberto Gomez, Juan Carlos Tirado, Aldo Amador Navarro Rojas, Maria Mercedes Castrejon Alba & Oleksandr Topachevskyi. (2013) Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health 13:1.
Crossref
Crossref
Rogier M. Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A. Farkouh & David R. Strutton. (2013) Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden. Clinical Therapeutics 35:2, pages 119-134.
Crossref
Crossref